seattle genetics

Citadel has published a report on Seattle Genetics (NASDAQ: SGEN) initiating coverage on the biotech company. In the report, Citadel wrote, "Despite our bearish view on the Adcetris market opportunity, we believe the product is approvable based on Phase II data. While we believe approval could be...

Jefferies is out with its report today on Seattle Genetics (NASDAQ: SGEN), raising its PT from $22 to $25. In a note to clients, Jefferies writes, "We are raising our sum-of-parts PT from $22 ($15 Adcetris+ $3 collaborations+ $4 cash) to $25 ($18 Adcetris+ $3 collaborations+ $4 cash), based on a...

Oppenheimer is out with its report today on Seattle Genetics (NASDAQ: SGEN), raising its PT from $21 to $24. In a note to clients, Oppenheimer writes, "Our new 12- to 18-month price target for SGEN is $24 based on a ten-year DCF valuation with a free cash flow estimate of ~$200M in 2020 and a...

“We reiterate our Overweight rating,” Piper Jaffray wrote in a report focusing on Seattle Genetics Inc. (NASDAQ: SGEN). “Our $20 price target is based on a $1.9 billion enterprise value plus YE'11E cash of $310 million. SGEN has no debt. We see upside to our target based on ADCETRIS approval.”...

According to Piper Jaffray, Seattle Genetics (NASDAQ: SGEN) Overweight rating is reiterated. Piper Jaffray said that at the European Hematology Association (EHA) meeting in London over the weekend, SGEN reported updated data on ADCETRIS. “The only ODAC panel on the calendar for this summer to...

Jefferies is out with its report today on Seattle Genetics (NASDAQ: SGEN), maintaining Buy. In a note to clients, Jefferies writes, "At ASCO, SGEN reported updated data on pivotal trials of its anti-CD30 antibody conjugate Adcetris in relapsed or refractory Hodgkin lymphoma and relapsed or...

According to Bank of America, Seattle Genetics (NASDAQ: SGEN) and partner Takeda are in regulatory discussions to finalize a registration study for Adcetris in cutaneous T cell lymphoma (CTCL). Bank of America said that the company has strong rationale for studying its drug in CTCL following data...

According to a recent report from Jefferies, A new protocol amendment is being implemented for the Adcentris expanded access program that will bode well for Seattle Genetics (NASDAQ: SGEN). The new protocol will allow second-line, pre-transplant patients to participate in the Adcentris expanded...

According to Brean Murray Carret, Seattle Genetics (NASDAQ: SGEN) Sell rating is reiterated. Brean Murray Carret reported that the 12-month price target is $11 and there are reasons to be bearish. Seattle Genetics closed yesterday at $15.86.

Jefferies is out with its report on Seattle Genetics (NASDAQ: SGEN), initiating SGEN at Buy. In a note to clients, Jefferies writes, "We are assuming coverage of SGEN with a Buy rating and a $22 price target. We can justify upside to the current valuation based on the prospects for SGEN's...

Jefferies & Company has raised the price target on Seattle Genetics (NASDAQ: SGEN) from $20 to $22 and maintains its Buy rating.

Oppenheimer has raised the price target on Seattle Genetics (NASDAQ: SGEN) from $16 to $17 and maintains its Outperform rating.

Piper Jaffray has released a report that focuses on next-gen antibody companies. “Over the past several years, we have seen significant consolidation in the biotherapeutic space,” Piper Jaffray writes. “We expect this trend to continue due to the scarcity of antibody technologies and the longer...

RBC Capital Markets has changed the price targets on the following companies: Seattle Genetics (NASDAQ: SGEN) Outperform, price target raised from $16 to $20 F5 Networks (NASDAQ: FFIV) Outperform, price target raised from $90 to $105 eBay (NASDAQ: EBAY) Outperform, price target raised from $25 to $...